Skip to main content
SpringerLink
Log in

Lipidsenkende Mittel

  • Chapter
Arzneiverordnungs-Report 2013

  • 1741 Accesses

Zusammenfassung

Erhöhte Cholesterinwerte des Low-Density-Lipoprotein (LDL)-Cholesterins gehören zusammen mit arterieller Hypertonie, Diabetes mellitus und Zigarettenkonsum zu den wichtigsten Risikofaktoren kardiovaskulärer Krankheiten. Zahlreiche kontrollierte klinische Studien dokumentieren, dass eine Senkung des LDL-Cholesterinspiegels die Risiken der koronaren Herzkrankheit vermindert.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 49.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner C, Krane V, Cass A, Craig J, Neal B, Jiang L, Hooi LS, Levin A, Agodoa L, Gaziano M, Kasiske B, Walker R, Massy ZA, Feldt-Rasmussen B, Krairittichai U, Ophascharoensuk V, Fellström B, Holdaas H, Tesar V, Wiecek A, Grobbee D, de Zeeuw D, Grönhagen-Riska C, Dasgupta T, Lewis D, Herrington W, Mafham M, Majoni W, Wallendszus K, Grimm R, Pedersen T, Tobert J, Armitage J, Baxter A, Bray C, Chen Y, Chen Z, Hill M, Knott C, Parish S, Simpson D, Sleight P, Young A, Collins R; on behalf of the SHARP Investigators (2011): The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 377: 2181–2192.

    Google Scholar 

  • Cholesterol Treatment Trialists’ (CTT) Collaborators (2005): Efficacy and safety of cholesterol- lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 366: 1267–1278.

    Google Scholar 

  • Cholesterol Treatment Trialists’ (CTT) Collaborators (2008): Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 371: 117–125.

    Google Scholar 

  • Cholesterol Treatment Trialists’ (CTT) Collaboration (2010): Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376: 1670–1681.

    Google Scholar 

  • Coronary Drug Project (1975): Clofibrate and niacin in coronary heart disease. JAMA 231: 360–381.

    Google Scholar 

  • De Lorgeril M, Salen P, Martin J-L, Monjaud I, Delaye J, Mamelle N (1999): Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction. Circulation 99: 779–785.

    Article  PubMed  CAS  Google Scholar 

  • Deutsche Gesellschaft für Kardiologie – Herz- und Kreislaufforschung (2011): ESC/EAS/ DGK Pocket-Leitlinien: Diagnostik und Therapie der Dyslipidämien. Internet: www.leitlinien.dgk.org/images/pdf/leitlinien_pocket/2012_pll_25_dys.pdf

  • European Medicines Agency (2013): European Medicines Agency confirms recommendation to suspend Tredaptive, Pelzont and Trevaclyn. Internet: www.emea.europa.eu/docs/en_GB/document_library/Press_release/2013/01/WC500137453.pdf

  • Grundy SM, Vega GL, McGovern ME, Tulloch BR, Kendall DM, Fitz-Patrick D, Ganda OP, Rosenson RS, Buse JB, Robertson DD, Sheehan JP; Diabetes Multicenter Research Group (2002): Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med 162: 1568–1576.

    Google Scholar 

  • Hayward A, Krumholz H, Zulman DM, Timbie JW, Vijan S (2010): Optimizing statin treatment for primary prevention of coronary artery disease. Ann Int Med 152: 69–77.

    Article  PubMed  Google Scholar 

  • Heart Protection Study Collaborative Group (2011): C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20,536 patients in the Heart Protection Study. Lancet 377: 469–476.

    Google Scholar 

  • HPS2-THRIVE Collaborative Group (2013): HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 34: 1279–1291.

    Google Scholar 

  • Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (2011): Ezetimib bei Hypercholesterinämie – Abschlussbericht A10-02. Internet: www.iqwig.de/download/A10-02_Abschlussbericht_Ezetimib_bei_Hypercholesterinaemie.pdf

  • Jun M, Foote C, Lv L, Neal B, Patel A, Nicholls S, Grobbee DE, Cass A, Chalmers A, Perkovic V (2010): Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 375: 1875–1884.

    Article  PubMed  CAS  Google Scholar 

  • Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, Visseren FL, Sijbrands EJ, Trip MD, Stein EA, Gaudet D, Duivenvoorden R, Veltri EP, Marais AD, de Groot E; ENHANCE Investigators (2008): Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 358: 1431–1443.

    Google Scholar 

  • Keech AC, Mitchell P, Summanen PA, O’Day J, Davis TME, Moffitt MS, Taskinen MR, Simes RJ, Tse D, Laatikainen LT, d’Emden MC, Crimet DC, O’Conell RL, Colman PG for the FIELD study investigators (2007): Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomized controlled trial. Lancet 370: 1678–1697.

    Google Scholar 

  • Klose G (2011): Möglichkeiten und Grenzen der modernen Lipidtherapie. Internist 52: 328–335

    Article  PubMed  CAS  Google Scholar 

  • Koenig W, Marx N, Thiery J, Klose G (2012): Kommentar zu den neuen Leitlinien (2011) der Europäischen Gesellschaft für Kardiologie zum Management von Dyslipidämien. Kardiologe 6: 210–216.

    Article  Google Scholar 

  • Krumholz HM, Hayward RA (2010): Shifting views on lipid lowering therapy. BMJ 341: 332–333.

    Article  CAS  Google Scholar 

  • Libby P (2013): Mechanisms of acute coronary syndromes and their implications for therapy. N Engl J Med 368: 2004–2013.

    Article  PubMed  CAS  Google Scholar 

  • Lipid Research Clinics Program (1984): Lipid Research Clinics Coronary Primary Prevention Trial Results. I. Reduction in incidence of coronary heart disease. II. Relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 251: 351–364, 365–374.

    Google Scholar 

  • Maccubbin D, Bays HE, Olsson AG, Elinoff V, Elis A, Mitchel Y, Sirah W, Betteridge A, Reyes R, Yu Q, Kuznetsova O, Sisk CM, Pasternak RC, Paolini JF (2008): Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia. Int J Clin Pract 62: 1959– 1970.

    Article  PubMed  CAS  Google Scholar 

  • Meaney A, Ceballos G, Asbun J, Solache G, Mendoza E, Vela A, Meaney E (2009): The VYtorin on Carotid intima-media thickness and overall arterial rigidity (VYCTOR) study. J Clin Pharmacol 49: 838–847.

    Article  PubMed  CAS  Google Scholar 

  • Merck (2012): Merck announces HPS2-THRIVE Study of Tredaptive™ (extended-release niacin/laropiprant) did not achieve primary endpoint. Internet: www.mercknewsroom.com/press-release/prescription-medicine-news/merck-announces-hps2-thrive-study-tredaptive-extended-relea

  • National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) (2002): Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106: 3143-3421. www.nhlbi.nih.gov/guidelines/cholesterol/index.htm

  • Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL (2013): Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol 61: 404–410.

    Article  PubMed  CAS  Google Scholar 

  • Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J et al.; Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators (2005): Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 352: 29–38.

    Google Scholar 

  • Rajamani K, Colman PG, Ping Li, L, Best JD, Voysey M, d’Emden CD, Laakso, M, John RB on behalf of the FIELD study investigators (2009): Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus ( FIELD study):a prespecified analysis of a randomized controlled trial. Lancet 373: 1780–1788.

    Google Scholar 

  • Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, Pfeffer MA, Braunwald E; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators (2005): C-reactive protein levels and outcomes after statin therapy. N Engl J Med 352: 20–28.

    Google Scholar 

  • Rossebø AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, Gerdts E, Gohlke- Bärwolf C, Holme I, Kesäniemi YA, Malbecq W, Nienaber CA, Ray S, Skjaerpe T, Wachtell K, Willenheimer R; SEAS Investigators (2008): N Engl J Med 359: 1343–1356.

    Google Scholar 

  • Scandinavian Simvastatin Survival Study Group (1994): Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease. The Scandinavian Simvastatin Survival Study (4S). Lancet 344: 1383–1389.

    Google Scholar 

  • Schönbeck U, Libby P (2004): Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? Circulation 109 (Suppl II): II 18–26.

    Google Scholar 

  • Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Mundl H, Nicholls SJ, Shah PK, Tardif JC, Wright RS; dal-OUTCOMES Investigators (2012): Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 367: 2089–2099.

    Google Scholar 

  • Shepherd J (2002): Resource management in prevention of coronary heart disease: optimising prescription of lipid-lowering drugs. Lancet 359: 2271–2273.

    Article  PubMed  Google Scholar 

  • Taylor AJ, Villines TC, Stanek EJ, Devine PJ, Griffen L, Miller M, Weissman NJ, Turco M (2009): Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 361: 2113–2122.

    Article  PubMed  CAS  Google Scholar 

  • The ACCORD Study Group (2010): Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 362: 1563–1574.

    Google Scholar 

  • The AIM-HIGH Investigators (2011): Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 365: 2255–2267.

    Google Scholar 

  • The Bezafibrate Infaction prevention (BIP) Study Group (2000): Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infaction Prevention (BIP) study. Circulation 102: 21–27.

    Google Scholar 

  • The FIELD study investigators (2005): Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366: 1849–1861.

    Google Scholar 

  • The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) (2011): ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J 32: 1769–818.

    Google Scholar 

  • Willett WC (2012): Dietary fats and coronary heart disease. J Intern Med 272: 13–24.

    Article  PubMed  CAS  Google Scholar 

  • Wiesner G, Grimm J, Bittner E (1999): Zum Herzinfarktgeschehen in der Bundesrepublik Deutschland: Prävalenz, Inzidenz, Trend, Ost-West-Vergleich. Gesundheitswesen 61 (Sonderheft 2): S72–S78.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Gemeinschaftspraxis Dres. Thomas Beckenbauer und Stefan Maierhof, Bremen, Am Markt 11, 28195

    Prof. Dr. med. Gerald Klose

  2. Pharmakologisches Institut, Universität Heidelberg, Heidelberg, Im Neuenheimer Feld 366, 69120

    Prof. Dr. med. Ulrich Schwabe

Authors
  1. Prof. Dr. med. Gerald Klose
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. med. Ulrich Schwabe
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pharmakologisches Institut, der Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg

    Ulrich Schwabe

  2. AOK NORDWEST Die Gesundheitskasse, Edisonstraße 70, 24145, Kiel

    Dieter Paffrath

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag Berlin, Heidelberg

About this chapter

Cite this chapter

Klose, G., Schwabe, U. (2013). Lipidsenkende Mittel. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2013. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-37124-0_31

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-37124-0_31

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-37123-3

  • Online ISBN: 978-3-642-37124-0

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation